The global mammalian cell fermentation technology market size accounted for USD 50.62 billion in 2024, grew to USD 55.13 billion in 2025 and is projected to surpass around USD 118.95 billion by 2034, representing a healthy CAGR of 8.92% between 2024 and 2034. The North America mammalian cell fermentation technology market size is calculated at USD 19.74 billion in 2024 and is expected to grow at a fastest CAGR of 9.06% during the forecast year.
The global mammalian cell fermentation technology market size accounted for USD 50.62 billion in 2024 and is anticipated to reach around USD 118.95 billion by 2034, growing at a CAGR of 8.92% between 2024 and 2034.
Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare
The global mammalian cell fermentation technology market size accounted for USD 50.62 billion in 2024 and is anticipated to reach around USD 118.95 billion by 2034, growing at a CAGR of 8.92% between 2024 and 2034.
The market for mammalian cell fermentation technology is dominated by North America, and this dominance is anticipated to continue for the duration of the forecast. A large portion of the rising demand for medical care that is specifically suited to the demands of each patient's body is supported by biologics. This increases demand for mammalian cell fermentation technology since it makes it possible to produce extremely targeted and potent treatments.
To ensure the safety and efficacy of a product, the FDA's strict regulatory standards call for the use of modern cell culture techniques. Manufacturers favour mammalian cell fermentation technology because it complies with these standards. Major biopharmaceutical companies are expanding their manufacturing facilities in North America which involves the incorporation of cutting-edge fermentation technologies to enhance production efficiency, further boosting the market’s growth.
Asia Pacific has one of the largest and fastest-growing mammalian cell fermentation technology markets globally. The biopharmaceutical sector has grown significantly in the Asia Pacific area, with more businesses concentrating on the creation of biologics and biosimilars. An essential technology for creating these intricate therapeutic proteins is mammalian cell fermentation.
The COVID-19 pandemic has highlighted the significance of the vaccine development and manufacture, which has led to an increase in the demand. Governments and pharmaceutical businesses in the region are making significant investments in mammalian cell fermentation since it is essential to the creation of virus vaccines. Collaboration between local and global pharmaceutical companies and research institutions is becoming more common. These partnerships often involve technology transfer and knowledge sharing, which contributes to the adoption of mammalian cell fermentation.
Mammalian cell fermentation is a bioprocess that is used in the biopharmaceutical sector to make various goods, such as therapeutic proteins, monoclonal antibodies, and vaccines. Several factors, including ongoing advancements in cell culture techniques, including perfusion systems, single-use bioreactors, and enhanced media formulations, are propelling the market's expansion. The development of mammalian cell fermentation technology has also been facilitated by outsourcing biopharmaceutical production to CMOs.
A survey released by the Personalized Medicine Coalition (PMC) revealed that in recent years, the number of personalized medicines available in the market more than doubled in the United States. Complex and varied biologics are needed due to the trend toward customized therapy, which increases the demand for cutting-edge mammalian cell fermentation technology.
The market for mammalian cell fermentation technology is anticipated to undergo a substantial change over the projected period due to the growing popularity of tissue engineering and regenerative medicine.
The demand for fermentation technologies is being propelled by the rising frequency of chronic diseases and the rising demand for biologics. Nearly half of all Americans, or 133 million people, are thought to have at least one chronic ailment, such as arthritis, heart disease, or hypertension.
The demand for biosimilars is also driving a significant increase in the mammalian cell fermentation technology market. These therapies are now essential for addressing several illnesses, including cancer.
| Report Coverage | Details |
| Market Size in 2024 | USD 50.62 Billion |
| Market Size by 2034 | USD 118.95 Billion |
| Growth Rate from 2024 to 2034 | CAGR of 8.92% |
| Largest Market | North America |
| Base Year | 2023 |
| Forecast Period | 2024 to 2034 |
| Segments Covered | Type, Application, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Surge in the development of personalized medicine
Personalizing medical therapy for each patient based on their genetic makeup, lifestyle choices, and particular illness characteristics is known as personalized medicine. This strategy has acquired a lot of popularity in recent years and holds the possibility of more effective treatments with fewer side effects. Mammalian cell fermentation technology and personalized medicine interact in a significant and revolutionary way. At its foundation, personalized medicine seeks to determine which course of action is best for every patient. This frequently entails the creation of highly targeted treatments, such as cell-based treatments, gene therapies, and monoclonal antibodies. Fermentation of mammalian cells is essential for the design of these cutting-edge therapeutics.
Personalized medicine relies on therapies targeting the molecular mechanisms underlying a patient's disease. Monoclonal antibodies, for example, are designed to bind to specific proteins on the surface of cells. These antibodies can be produced through mammalian cell fermentation, ensuring high specificity and quality. Thus, the rising emphasis on personalized medicine acts as a major driver for the market’s expansion.
High capital costs
High capital expenditures are a key barrier for the mammalian cell fermentation technology market, which is essential to the pharmaceutical and biotechnology sectors. Mammalian cell fermentation facilities require a significant financial commitment to establish and maintain, frequently presenting a significant barrier to entry for smaller businesses and startups.
The demand for specialized infrastructure is one of the main factors influencing these capital expenses. Bioreactors, which are substantial, intricate tanks created to offer a regulated environment for cell growth and product creation, are often where mammalian cell fermentation occurs. These bioreactors adhere to strict specifications for, among other things, temperature, pH, oxygenation, and agitation. It will cost a lot of money to design and validate these bioreactors, so they comply with regulatory requirements.
The requirement for highly skilled employees is another factor raising capital expenses. Mammalian cell fermentation facilities must be operated and maintained by a staff with specialist knowledge of cell culture procedures, bioprocess engineering, and regulatory compliance. The competitive salaries these experts charge drive up the whole cost even more.
Development of gene and cell therapy
Cell and gene therapies are innovative methods for treating a range of inherited and acquired disorders, with the potential to provide cures instead of symptom relief. The manufacture of crucial elements for these therapies, including viral vectors and therapeutic cells, is greatly aided by mammalian cell fermentation technology. In order to introduce, replace, or repair faulty genes in a patient's cells, gene therapy is used.
Viral vectors modified viruses made to carry therapeutic genes into target cells are frequently used in this process. It takes a lot of work to produce these viral vectors at a volume appropriate for clinical trials and commercialization. A regulated environment is provided by mammalian cell fermentation for the expansion of host cells and the reproduction of these viral vectors.
Contrarily, cell therapy includes giving living cells to the body to replace or mend damaged tissues or strengthen the immune system's defences against diseases like cancer. Mammalian cell fermentation is required for the creation of therapeutic cells for cell therapy applications, such as CAR-T cells for cancer treatment. These cells can be expanded with this method in bioreactors under precisely regulated conditions to reach the necessary cell number and quality.
In 2023, the Chinese Hamster Ovary (CHO) cell fermentation segment had the most significant share, and it is anticipated that it will continue to dominate during the forecast period for the creation of biopharmaceuticals, such as monoclonal antibodies and therapeutic proteins. The fermentation process can be strongly impacted by elements including specific productivity, growth traits, and genetic stability. Cell lines with high genetic stability and productivity are selected. CHO cells need a suitable culture media that is full of nutrients, such as carbohydrates, amino acids, and vitamins, in order to develop and produce protein. Optimizing the media promotes ideal cell growth.
In the global market, the Human Embryonic Kidney (HEK) cell fermentation segment is seen as having the fastest rate of growth. Several vital elements, notably those related to the biotechnology and pharmaceutical industries, have an impact on the expansion of human embryonic kidney cell fermentation. The combination of these factors propels research and development in this field, enabling improvements in bioprocessing and the creation of useful biopharmaceuticals. Demand for biopharmaceuticals, such as monoclonal antibodies, vaccines, and gene treatments, is on the rise, which has increased the demand for scalable and effective cell culture methods. A flexible platform is provided by human embryonic kidney cells for the production of these therapies.
The monoclonal antibodies segment had the most shares in 2023. The growth of monoclonal antibodies (MABs) as a therapeutic class has been remarkable in recent years, driven by several key factors that have converged to create a highly favorable environment for their development and utilization. Genetic engineering and biotechnology developments have significantly increased the manufacture of MABs. These antibodies are particularly beneficial for treating a variety of disorders because they can be made precisely and specifically to bind to particular antigens on cells.
There are many therapeutic targets that have been identified as a result of the growing understanding of the immune system and its function in conditions including cancer, autoimmune disorders, and infectious diseases. These particular molecules can be targeted by MABs, providing a customized course of treatment.
In 2022, Sanofi S.A. and Blackstone Life Sciences collaborated to hasten the development of a subcutaneous Sarclisa mAb formulation for the treatment of multiple myeloma patients.
In the global market, the recombinant proteins segment is anticipated to be the one that is expanding most quickly. Recombinant proteins are genetically engineered proteins made by fusing genetic material from many sources. Usually, this fusion involves inserting a particular gene into a host cell, such yeast or bacteria, to make the desired protein. The creation and use of the recombinant proteins are supported by a number of important factors. For therapeutic purposes, the pharmaceutical industry mainly relies on the recombinant proteins.
These proteins operate as the main therapeutic components of a variety of medications, such as insulin for the diabetes and monoclonal antibodies for cancer. Recombinant proteins are crucial instruments in scientific study and development. They help to comprehend biology and pave the door for new discoveries by studying cellular processes, protein interactions, and gene function.
Recombinant proteins are used in the production of many vaccinations, including those against hepatitis B and the human papillomavirus (HPV). These proteins effectively guard against disease by stimulating the immune system.
Segments Covered in the Report:
By Type
By Application
By Geography
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Mammalian Cell Fermentation Technology Market
5.1. COVID-19 Landscape: Mammalian Cell Fermentation Technology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Mammalian Cell Fermentation Technology Market, By Type
8.1. Mammalian Cell Fermentation Technology Market, by Type, 2024-2034
8.1.1. Chinese Hamster Ovary (CHO) Cell Fermentation
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Human Embryonic Kidney (HEK) Cell Fermentation
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Baby Hamster Kidney (BHK) Cell Fermentation
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Murine Myeloma Cell Fermentation
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Mammalian Cell Fermentation Technology Market, By Application
9.1. Mammalian Cell Fermentation Technology Market, by Application, 2024-2034
9.1.1. Monoclonal Antibodies
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Recombinant Proteins
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Vaccines
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Hormones
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Enzymes
9.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Mammalian Cell Fermentation Technology Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2021-2034)
10.1.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Application (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2021-2034)
10.5.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Application (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Application (2021-2034)
Chapter 11. Company Profiles
11.1. Thermo Fisher Scientific, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Merck KGaA
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Danaher
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Lonza
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Sartorius AG
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. AstraZeneca
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Bristol-Myers Squibb
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Amgen
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Gilead Sciences
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample